Board of Directors

  • Abigail L. Jenkins, M.S.

    President and Chief Executive Officer

    Abigail “Abbey” L. Jenkins, M.S., joined Gamida Cell as President, CEO and board member in September 2022. Ms. Jenkins brings over 20 years of leadership experience in the biopharmaceutical industry delivering life-enhancing therapies from research to commercialization for patients in need. Prior to joining Gamida Cell, she served as the chief commercial and business officer at Lyndra Therapeutics, where she established and led global commercial, business development, corporate strategy and portfolio management across multiple therapeutic areas. Prior to Lyndra, she served as senior vice president and business unit head of vaccines at Emergent BioSolutions, where she oversaw the company’s largest therapeutic division from discovery through commercialization. Ms. Jenkins also served as chief commercial officer and U.S. business head at Aquinox Pharmaceuticals. Additionally, she has held senior commercial and business development positions at Relypsa, Actavis, Pfizer and Medimmune/AZ.

    Ms. Jenkins holds a Master of Science in biotechnology and biotech business enterprise from The Johns Hopkins University, a Bachelor of Arts in psychology and biology from Indiana University, and a certificate of achievement in General Management as a Kellogg Executive Scholar. In September, she was recognized by PharmaVoice as one of the top 100 Most Inspiring Leaders, Disrupter category, for change-agents who are defining excellence in leadership in the biopharma industry.

  • Julian Adams, Ph.D.


    Julian Adams retired from his role of CEO from Gamida Cell in September 2022 as part of a planned succession. Julian continues to serve on Gamida Cell’s Board of Directors. Julian joined Gamida Cell’s leadership team as Chief Executive Officer in November 2017, bringing more than 30 years of drug discovery and development experience to his role. He has served on the board since September 2016. Prior to his CEO appointment, Julian served as President and Chief Scientific Officer at Clal Biotechnology Industries (CBI), where he oversaw the Boston office, evaluating investment opportunities and supporting portfolio companies, including Gamida Cell. Before joining CBI, he served as the President of Research and Development at Infinity Pharmaceuticals, where he built and led the company’s R&D efforts. Julian also served as Senior Vice President of Drug Discovery and Development at Millennium Pharmaceuticals, where he played a key role in the discovery of Velcade® (bortezomib), a therapy widely used for treatment of the blood cancer, multiple myeloma. Earlier in his career, he was credited with discovering Viramune® (nevirapine) for HIV at Boehringer Ingelheim. He has also held senior leadership roles in research and development at LeukoSite and ProScript.

    Julian has won several awards for his drug development efforts throughout his career, holds more than 40 patents from the United States Patent and Trademark Office and has authored more than 100 papers and book chapters in peer-reviewed journals. Julian holds a B.S. from McGill University and a Ph.D. from the Massachusetts Institute of Technology. He also holds a Sc.D., honoris causa, from McGill University.

  • Ivan Borrello, M.D.


    Ivan Borrello, M.D joined Gamida Cell’s Board of Directors in June 2022. Dr. Borrello has served as an Associate Professor of Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine since 2008. He is also an Attending Physician at The Johns Hopkins Hospital and Director of the Cellular Therapeutics and Multiple Myeloma programs. Dr. Borrello is a co-founder of WindMIL Therapeutics where he has served as senior clinical advisor since 2014, and is a co-founder of Meridian Therapeutics where he has served as senior clinical advisor since 2021. From 2001 to 2008, he was an Assistant Professor of Immunotherapy and Hematopoiesis, Hematologic Malignancies at Johns Hopkins Oncology Center. Dr. Borrello received a B.A. in Biology from Catholic University and an M.D. from the Medical College of Virginia.

  • Robert Blum


    Robert Blum joined Gamida Cell’s Board of Directors as Chairman in September 2018, bringing 40 years of experience in the biopharmaceutical industry. Mr. Blum started Cytokinetics in 1998 and served in roles of increasing responsibility before being appointed President and Chief Executive Officer in 2007. Previously, he held senior positions in business and commercial development at COR Therapeutics and roles of increasingly responsibility in sales, marketing and planning functions at Marion Laboratories and Syntex Corporation. Additionally, Mr. Blum served on the National Board of the American Committee of the Weizmann Institute of Science and established the Blum Family Venture Philanthropy Fund to advance translational science discoveries with potential to benefit the Israeli life sciences economy. He serves on the Board of San Francisco’s Jewish Family & Children’s Services and Temple Emanu-el and previously served on the Board of other Bay Area Jewish community non-profits. He founded and chaired the Business Leadership Council of the Jewish Community Federation and is a Founding Board Member of Life Science Cares-Bay Area. Mr. Blum is a Henry Crown Fellow of the Aspen Institute, awarded in recognition of his leadership in corporate and civic responsibilities.

    Mr. Blum holds bachelor’s degrees in human biology and economics from Stanford University and an MBA from Harvard Business School.

  • Kenneth Moch


    Kenneth I. Moch has more than 35 years of experience in managing and financing biomedical technologies, and has played a key role in building five life science companies. He currently serves as president of Euclidean Life Science Advisors, LLC, where he provides management and advisory services for early-stage biotechnology companies. From 2016 to 2020, Mr. Moch served as the president and chief executive officer of Cognition Therapeutics, Inc., a company developing therapies for Alzheimer’s disease. He previously was the managing partner of The Salutramed Group, LLC, and served as the chief executive officer of several life sciences companies, including Chimerix, Inc., an antiviral therapeutics company focused on stem cell transplantation, and Biocyte Corporation, which pioneered the use of cord blood stem cell storage and transplantation. He began his career in biotech as a co-founder of The Liposome Company, the first lipid nanoparticle company.  Mr. Moch also serves as a director of Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE). In the public policy arena, Mr. Moch served for over 15 years as a member of the governing board of the Biotechnology Innovation Organization, including serving as Chair of BIO’s Bioethics Committee, and is a previous Chairman of BioNJ. He is a Founding Member of the New York University Working Group on Compassionate Use and Pre-Approval Access, and a Faculty Affiliate of the Division of Medical Ethics, Department of Population Health, NYU School of Medicine. Mr. Moch holds an A.B. in Biochemistry from Princeton University and an M.B.A. with emphasis in Finance and Marketing from the Stanford Graduate School of Business.

  • Shawn Cline Tomasello


    Shawn Cline Tomasello joined Gamida Cell’s Board of Directors in June 2019, bringing extensive experience in leading successful commercial activities at several pharmaceutical companies. Most recently, she served as Chief Commercial Officer of Kite Pharma, now part of Gilead Sciences, where she oversaw the global commercialization of Yescarta®, the first approved CAR-T therapy for non-Hodgkin lymphoma. Prior to joining Kite, Ms. Tomasello was Chief Commercial Officer of Commercial and Medical Affairs at Pharmacyclics, now part of AbbVie, where she led commercial and medical affairs activities for Imbruvica®. Ms. Tomasello currently serves on the Boards of Diplomat Pharmacy, Centrexion Therapeutics and Oxford BioTherapeutics.

    Ms. Tomasello holds a bachelor’s degree in marketing from the University of Cincinnati and an MBA from Murray State University.

  • Naama Halevi-Davidov, Ph.D.


    Dr. Naama Halevi Davidov joined Gamida Cell’s Board of Directors in January 2022. Dr. Halevi Davidov served as a Financial Advisor to Healthy IO Ltd., a manufacturer and marketer of medical equipment from March 2019 through April 2021, to Gloat Ltd., a talent marketplace platform, from March 2020 through November 2021, and to Joytunes Ltd., a B2C Music Teaching App, since April 2021. Prior to that, Dr. Halevi Davidov was Chief Financial Officer of Kaltura, Inc. from November 2012 to August 2017. Dr. Halevi Davidov serves on the board of Kaltura, Inc. and has also served on the board of its subsidiary, Kaltura Asia Pte Ltd. since February 2015.

    Dr. Halevi Davidov is a Certified Public Accountant in Israel. She received a Ph.D. in Strategy from Tel Aviv University in 2012, a Master’s in Business Administration from Tel Aviv University in 2002 and Bachelor of Arts in Accounting and Economics from Tel Aviv University in 2000.

  • Stephen Wills


    Stephen Wills joined Gamida Cell’s Board of Directors as a Director in 2019, and currently serves as the Chief Financial Officer, Chief Operating Officer, Treasurer and Secretary of Palatin Technologies, Inc., a publicly-traded biopharmaceutical company developing peptide therapeutics. Prior to joining Palatin, Mr. Wills served as Executive Chairman and Interim Principal Executive Officer of Derma Sciences, Inc., a provider of advanced wound care products, which has since been acquired by PSI. He was also previously the Chief Financial Officer of Derma Sciences, and served on the company’s Board of Directors. Mr. Wills currently serves as Chairman of the Board of Directors of MediWound Ltd., and on the Board of Directors of Amryt Pharma.

    Mr. Wills is a certified public accountant. He holds a bachelor’s degree in accounting from West Chester University and a master’s degree in taxation from Temple University.

  • Anat Cohen-Dayag, Ph.D.


    Dr. Anat Cohen-Dayag joined Gamida Cell’s Board of Directors in January 2022, with over 25 years of experience in the biotech industry, both in R&D and executive leadership roles. Dr. Cohen-Dayag is President and Chief Executive Officer and a member of the Board of Directors of Compugen Ltd. Under her leadership, Compugen transformed from a service provider in the field of computational biology to a therapeutic discovery and development company advancing an innovative immuno-oncology pipeline originating from the company’s computational discovery platforms. Prior to Compugen, Dr. Cohen-Dayag served as Head of R&D and was a member of the executive management team of Mindsense Biosystems Ltd. She also serves on the board of Pyxis Diagnostics, a private biotechnology company located in Jerusalem, Israel focused on developing a unique platform to identify predictive biomarkers in the field of immuno-oncology.

    Dr. Cohen-Dayag holds a B.Sc. in Biology from Ben-Gurion University, and an M.Sc. in Chemical Immunology and a Ph.D. in Cellular Biology, both from the Weizmann Institute of Science.